


Supplemental Information

**Liver-Targeted AAV8 Gene Therapy Ameliorates
Skeletal and Cardiovascular Pathology
in a Mucopolysaccharidosis IVA Murine Model**


Kazuki Sawamoto, Subha Karumuthil-Meleshil, Shaukat Khan, Molly Stapleton, Joseph T. Bruder, Olivier Danos, and Shunji Tomatsu

Supplemental Figure 1.


A



B




Supplemental Figure 2.




Group	AAV vector genome copies per diploid genome
KO (untreated)	1.57 ± 1.21 (n = 6)
MTOL (untreated)	0.083 ± 0.12 (n = 4)
WT (untreated)	0.063 ± 0.11 (n = 6)
KO (AAV-TBG-hGALNS)	242.23 ± 114.08 (n = 7)
KO (AAV-TBG-D8-hGALNS)	182.36 ± 71.85 (n = 6)
MTOL (AAV-TBG-hGALNS)	309.51 ± 112.14 (n = 5)
MTOL (AAV-TBG-D8-hGALNS)	305.36 ± 147.82 (n = 4)

Supplemental Figure 3.




Supplemental Figure 4.




Supplemental Figure 5.

A



B



Supplemental Figure 6.

